First hormone-free male birth control pill clears another milestone
While the FDA has approved over 20 different categories of contraceptives, only two are available for men to prevent ...
New Scientist1d
Fake pills ease PMS symptoms even when you know they're placebos
Women with premenstrual syndrome reported big improvements in their symptoms after taking placebo pills, despite knowing they did not contain any active ingredients ...
FDA approves first new antibiotic for UTIs in nearly 30 years
The drug Blujepa, from drugmaker GSK, provides a new treatment option as bacteria increasingly become resistant to the ...
The Case For Hims & Hers: Diversification And Growth Beyond Semaglutide
Hims & Hers has risen since November 2024, outperforming the S&P 500. Click here to see why HIMS stock is a Buy.
INQUIRER.net USA on MSN5d
This cutting edge hair loss treatment is a repurposed drug from 1990s
The latest trend in treating hair loss may sound familiar — essentially, it’s a repurposed drug first popularized in the ...
Hims & Hers Has Superstar Potential, But It Will Take A Lot To Get There
Hims & Hers is shifting towards personalized medicine with AI-backed solutions. Find out why HIMS stock is buyable despite ...